BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol. 2014;49:470-480. [PMID: 23525978 DOI: 10.1007/s00535-013-0779-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Yang Q, Shi YU, Yang Y, Lou G, Lv F. Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysis. Biomed Rep 2015;3:269-75. [PMID: 25798251 DOI: 10.3892/br.2015.415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Megapanou E, Florentin M, Milionis H, Elisaf M, Liamis G. Drug-Induced Hypophosphatemia: Current Insights. Drug Saf 2020;43:197-210. [DOI: 10.1007/s40264-019-00888-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7(11): 1541-1552 [PMID: 26085913 DOI: 10.4254/wjh.v7.i11.1541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
4 Zhao J, Feng WG, Wei Z, Zhou J, Chen XY, Zhang ZL. Follow-Up of Adefovir Dipivoxil Induced Osteomalacia: Clinical Characteristics and Genetic Predictors. Front Pharmacol 2021;12:636352. [PMID: 33995038 DOI: 10.3389/fphar.2021.636352] [Reference Citation Analysis]
5 Sano T, Kawaguchi T, Ide T, Amano K, Kuwahara R, Arinaga-Hino T, Torimura T. Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B. Life (Basel) 2021;11:263. [PMID: 33806752 DOI: 10.3390/life11030263] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Lee JG, Lee J, Lee JJ, Song SH, Ju MK, Choi GH, Kim MS, Choi JS, Kim SI, Joo DJ. Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation. Medicine (Baltimore) 2015;94:e1569. [PMID: 26402818 DOI: 10.1097/MD.0000000000001569] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Cai S, Yu T, Jiang Y, Zhang Y, Lv F, Peng J. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Clin Exp Med 2016;16:429-36. [PMID: 26164128 DOI: 10.1007/s10238-015-0373-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
8 Lin TF, Hsu PI, Lin KH, Tsay FW, Tsai TJ, Chen YH, Yu HC. Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy. Gastroenterol Res Pract 2017;2017:4192169. [PMID: 28757867 DOI: 10.1155/2017/4192169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Kim SB, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Han KH. Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol Hepatol. 2016;31:241-247. [PMID: 26204913 DOI: 10.1111/jgh.13046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
10 Sobhonslidsuk A, Numthavaj P, Wanichanuwat J, Sophonsritsuk A, Petraksa S, Pugasub A, Jittorntam P, Kongsomgan A, Roytrakul S, Phakdeekitcharoen B. Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Chronic Hepatitis B. Biomed Res Int. 2017;2017:4327385. [PMID: 29214169 DOI: 10.1155/2017/4327385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Demir M, Guner R, Dogan Z, Kucukazman M, Poyrazoglu OK, Biyik M, Ozturk NA, Aydogan T, Coban S, Kocaman O, Sapmaz F, Gokturk SH, Karaca C, Demirezer A, Tanoglu A, Yildirim B, Altinbas A, Atak BM, Cosar AM, Alkan E; Other collaborators. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther. 2015;41:310-319. [PMID: 25982037 DOI: 10.1111/apt.13036] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
12 Sobhonslidsuk A, Wanichanuwat J, Numthavaj P, Sophonsritsuk A, Petraksa S, Pugasub A, Jittorntam P, Kongsomgan A, Roytrakul S, Phakdeekitcharoen B. Nucleotide Analogue-Related Proximal Renal Tubular Dysfunction during Long-Term Treatment of Chronic Hepatitis B: A Cross-Sectional Study. Gastroenterol Res Pract 2016;2016:2952635. [PMID: 27872640 DOI: 10.1155/2016/2952635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Wu X, Cai S, Li Z, Zheng C, Xue X, Zeng J, Peng J. Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis. Virol J 2016;13:64. [PMID: 27062520 DOI: 10.1186/s12985-016-0522-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
14 Kaneko S, Hatakeyama Y, Tsukamoto Y. Acquired Fanconi syndrome due to long-term adefovir administration in a patient with IgG-kappa monoclonal gammopathy and kappa Bence-Jones protein. CEN Case Rep 2014;3:188-94. [PMID: 28509196 DOI: 10.1007/s13730-014-0115-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Yu HC, Lin KH, Tsay FW, Tsai TJ, Wu PC, Chen YH, Chen YH. Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies. PLoS One 2020;15:e0237586. [PMID: 32785260 DOI: 10.1371/journal.pone.0237586] [Reference Citation Analysis]
16 Ozoya OO, Sokol L, Dalia S. Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies. J Clin Transl Hepatol 2016;4:143-50. [PMID: 27350944 DOI: 10.14218/JCTH.2016.00005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
17 Perrella A, Lanza A, Pisaniello D, Dicostanzo G, Calise F, Cuomo O. Telbivudine Prophylaxis for Hepatitis B Virus Recurrence After Liver Transplantation Improves Renal Function. Transplantation Proceedings 2014;46:2319-21. [DOI: 10.1016/j.transproceed.2014.07.058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Luo Q, Deng Y, Cheng F, Kang J, Zhong S, Zhang D, Zeng W. Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. Medicine (Baltimore) 2016;95:e5578. [PMID: 27977591 DOI: 10.1097/MD.0000000000005578] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
19 Sun L, Yi D, Sun W, Wang C. Retrospective analysis of the clinical characteristics of adefovir dipivoxil-induced Fanconi's syndrome in the Chinese population. J Clin Pharm Ther 2020;45:722-8. [PMID: 32406123 DOI: 10.1111/jcpt.13154] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Chen N, Zhang JB, Zhang Q, Zhao YP, Li LY, Liu LW, Yu F, Yu X, Peng T, Tang KX. Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. BMC Pharmacol Toxicol 2018;19:23. [PMID: 29769119 DOI: 10.1186/s40360-018-0212-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Jia HY, Ding F, Chen JY, Lian JS, Zhang YM, Zeng LY, Xiang DR, Yu L, Hu JH, Yu GD, Cai H, Lu YF, Zheng L, Li LJ, Yang YD. Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. World J Gastroenterol 2015; 21(12): 3657-3662 [PMID: 25834334 DOI: 10.3748/wjg.v21.i12.3657] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
22 Koda R, Tsuchida M, Iino N, Narita I. Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency. Intern Med 2019;58:821-5. [PMID: 30333420 DOI: 10.2169/internalmedicine.1698-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Ning L, Lin W, Hu X, Fan R, Liang X, Wu Y, Shen S, Yu R, Sun J, Hou J. Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. J Viral Hepat 2017;24:1043-51. [PMID: 28581186 DOI: 10.1111/jvh.12733] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
24 Li Z, Shen C, Wang Y, Wang W, Zhao Q, Liu Z, Wang Y, Zhao C. Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B. Medicine (Baltimore) 2016;95:e5264. [PMID: 27858892 DOI: 10.1097/MD.0000000000005264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Sinakos E, Antoniadis N, Goulis I, Cholongitas E, Kiapidou S, Tsakni E, Vasiliadis T, Papanikolaou V, Akriviadis E. Nucleos(t)ide analogues for the prevention of hepatitis B recurrence after liver transplantation do not affect serum phosphorus levels. Ann Gastroenterol 2016;29:208-13. [PMID: 27065734 DOI: 10.20524/aog.2016.0014] [Reference Citation Analysis]
26 Deray G, Buti M, Gane E, Jia J, Chan HLY, Craxi A, Piratvisuth T, Pol S. Hepatitis B Virus Infection and the Kidney: Renal Abnormalities in HBV Patients, Antiviral Drugs Handling, and Specific Follow-Up. Advances in Hepatology 2015;2015:1-11. [DOI: 10.1155/2015/596829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]